<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162812</url>
  </required_header>
  <id_info>
    <org_study_id>TOP Trial</org_study_id>
    <secondary_id>CE1141</secondary_id>
    <nct_id>NCT00162812</nct_id>
  </id_info>
  <brief_title>Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin</brief_title>
  <acronym>TOP</acronym>
  <official_title>Prospective Evaluation of Topoisomerase II Alpha Gene Amplification and Protein Overexpression as Markers Predicting the Efficacy of Epirubicin in the Primary Treatment of Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Paul Strauss</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier du Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Louis Cathy - Baudour - Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HIS - Site Etterbeek - Ixelles - Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Saint Pierre Ottignies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Ste Elisabeth - Namur - Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feculdade de Medicina da Universidade de Sao Paulo - Brasil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      prospective evaluation of topoisomerase II alpha gene amplification and protein&#xD;
      overexpression as markers predicting the efficacy of epirubicin in the primary treatment of&#xD;
      breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical evaluation of topo II a as a predictive marker: Preliminary results from a clinical&#xD;
      study suggest that complete remission after treatment with anthracyclines for advanced breast&#xD;
      cancer is observed only in case of topo II a gene amplification (7 complete remissions, all&#xD;
      in patients with topo II a gene amplified tumors, no complete remissions in patients with a&#xD;
      normal or deleted topo II a gene).&#xD;
&#xD;
      Moreover, our group has analyzed the predictive value of topo II a in a population of&#xD;
      node-positive breast cancer patients randomly treated either with anthracyclines or with CMF&#xD;
      (Belgian cooperative trial). In a first study, topo II a was evaluated by&#xD;
      immunohistochemistry, which allows the detection of topo II a protein expression. The results&#xD;
      of this study suggested that patients deriving the highest benefit from anthracyclines were&#xD;
      those in which topo II a protein is immunostained in more than 10% of tumor cells. The main&#xD;
      findings of this study should be seen as hypothesis-generating because of the limited number&#xD;
      of patients evaluated (about fifty in each study arm) and because topo II a protein levels&#xD;
      depend on gene amplification as well as on tumor proliferation rate. Therefore, topo II a&#xD;
      protein expression does not necessarily reflect topo II a gene status.&#xD;
&#xD;
      The second study run by our group was based on the same series of patients evaluated in the&#xD;
      first study, but, this time, both HER-2 and topo II a genes were evaluated by fluorescence&#xD;
      in-situ hybridization (FISH), which allows the detection of gene aberrations. The main&#xD;
      findings of the second study were quite consistent with the pre-clinical data suggesting that&#xD;
      only HER-2 amplified/topo II a amplified tumours show great sensitivity to anthracyclines&#xD;
      while the efficacy of these same agents in HER-2 amplified/topo II a non-amplified tumors is&#xD;
      comparable to the efficacy of other drugs or regimens like CMF.&#xD;
&#xD;
      Nevertheless, although the results reported in this study bring some additional support to&#xD;
      the hypothesis of topo II a as a marker predicting the efficacy of anthracyclines, no&#xD;
      definitive conclusions can be drawn because of the fairly limited number of patients&#xD;
      evaluated, and the retrospective nature of the analyses.&#xD;
&#xD;
      The present study protocol: Supported by &quot;in-vitro&quot; and preliminary &quot;in-vivo&quot; data, briefly&#xD;
      summarized above, this study is designed to test prospectively the value of topo II alpha&#xD;
      gene amplification and protein overexpression in predicting the efficacy of anthracyclines.&#xD;
      To our knowledge this is the only prospective trial worldwide which is attempting to&#xD;
      prospectively clarify the predictive value of this interesting biological marker. This study&#xD;
      could have important practical implications in the daily clinical management of early breast&#xD;
      cancer patients because, if the trial confirms that topo II a gene amplification and/or&#xD;
      protein overexpression are associated with high efficacy of anthracyclines, while topo II a&#xD;
      normal/deleted gene and low protein content are associated with modest efficacy, an important&#xD;
      step forward in the direction of anthracycline &quot;tailoring&quot; would be accomplished.&#xD;
&#xD;
      The practical advantage of this approach would be to use anthracyclines primarily in patients&#xD;
      who are supposed to derive the largest benefit, thus sparing the long-term&#xD;
      anthracycline-related toxicity (i.e. secondary acute myeloid leukemia, cardiac dysfunction,&#xD;
      and amenorrhea/sterility in case of fertile women) to those patients for whom no significant&#xD;
      gain in antitumor activity is anticipated.&#xD;
&#xD;
      To reach this ambitious aim, early breast cancer patients with tumors of at least 2 cm&#xD;
      (defined by breast ultrasound) will be evaluated for topo II a gene and protein expression.&#xD;
      For this purpose, a pre-treatment biopsy (tru-cut) will be performed and topo II a gene will&#xD;
      be evaluated on fixed samples by FISH. The use of a triple probe will allow the concomitant&#xD;
      evaluation of the HER-2 gene status. Topo II a protein will be evaluated by&#xD;
      immunohistochemistry (IHC). Afterwards, all patients, independently of the topo II a gene and&#xD;
      protein status, will be treated with single-agent epirubicin Eligibility criteria will allow&#xD;
      the participation of patients for whom the use of an anthracycline-based adjuvant therapy&#xD;
      would have been most probably proposed after breast cancer surgery, mainly because of&#xD;
      estrogen receptor (ER) negativity. Therefore, no overtreatment with anthracyclines will occur&#xD;
      in this group of patients. Pathological complete response (pCR) to epirubicin will be&#xD;
      correlated with the topo II a gene and protein status. The study has two biological&#xD;
      hypotheses, one for the subgroup of patients with ER negative/HER-2 amplified tumors, the&#xD;
      other one for the subgroup of patients with ER negative/HER-2 non amplified tumors.&#xD;
&#xD;
        1. st hypothesis: Patients with ER negative/HER-2 amplified tumors: In this subgroup of&#xD;
           patients, topo II a gene will be amplified in about 40% of cases. We hypothesize that in&#xD;
           topo II a amplified tumors a three-fold increase in pCR rate will be observed, as&#xD;
           opposed to the pCR rate in tumors with topo II a normal or deleted gene.&#xD;
&#xD;
        2. nd hypothesis : Patients with ER negative/HER-2 non amplified tumors: In this subset of&#xD;
           patients, almost no topo II a gene aberrations will be found based on previous data&#xD;
           discussed above. However, recent data reported by C. Sotiriou et al using cDNA&#xD;
           microarrays, suggest that in this subset of ER-negative HER-2 negative tumors, also&#xD;
           defined as the basal-like subset, two distinct subgroups can be identified (i.e.&#xD;
           basal-like 1 and 2). While basal-like 1 tumors show a high proliferation rate and high&#xD;
           levels of topo II a RNA, basal-like 2 tumors have a moderate-low proliferation rate and&#xD;
           normal levels of topo II a RNA. We hypothesize that the topo II a RNA overexpression in&#xD;
           basal-like 1 tumors is not related to topo II a gene amplification because no&#xD;
           concomitant HER-2 gene amplification is reported in this subset of tumors. The second&#xD;
           study hypothesis is that in ER negative/HER-2 non amplified tumors with topo II a&#xD;
           protein overexpression, a 2.5 fold increase in pCR rate will be observed, as opposed to&#xD;
           the pCR rate in tumors with low topo II a protein content.&#xD;
&#xD;
      A tumor sample drawn at the time of pre-treatment biopsy will be frozen and used to perform&#xD;
      oligonucleotide based microarrays (Affymetrix). This technique allows the evaluation of&#xD;
      thousands of genes and ultimately provides us with the tumor genetic profile. Homogeneous&#xD;
      genetic profiles (genetic clusters) that might be identified, will be correlated with the&#xD;
      efficacy of single-agent epirubicin. This correlation will allow us to address the secondary&#xD;
      end-point of this study, which is the identification of other genes or eventually a genetic&#xD;
      profile playing a role in the determination of sensitivity to anthracyclines. Among the genes&#xD;
      that could interfere with sensitivity to anthracyclines, p-53 seems to deserve special&#xD;
      attention. Indeed, &quot;in-vitro&quot; data suggest that at least some p-53 mutated tumors are poorly&#xD;
      sensitive to anthracyclines, primarily because anthracycline-induced apoptosis is prevented.&#xD;
      Interestingly, p-53 mutated tumors display frequently HER-2 gene amplification and therefore&#xD;
      topo II a gene amplification (23). Accordingly, p-53 mutations could hamper response to&#xD;
      anthracyclines even in tumors carrying topo II a gene amplification. This hypothesis will&#xD;
      also be explored in the present study, because p-53 mutations will be evaluated by DNA&#xD;
      sequencing, and the efficacy of epirubicin in topo II a amplified and non-amplified tumors&#xD;
      will be correlated with p-53 status.&#xD;
&#xD;
      Additionally, patients with inflammatory breast cancer will be treated with dense&#xD;
      administration of epirubicin (100 mg/m2/2 weeks). We keep the same drug as for early breast&#xD;
      cancer but we use a slightly more aggressive regimen with a higher dose-density. The&#xD;
      feasibility of the administration of epirubicin 100 mg/m2 every two weeks with&#xD;
      granulocyte-growth factor support has been shown in the neoadjuvant, metastatic and adjuvant&#xD;
      settings with acceptable toxicity. This neoadjuvant epirubicin regimen may be completed by&#xD;
      adjuvant chemotherapy, such as taxane-based regimens, since the sequential approach&#xD;
      (anthracyclines and taxanes) has been suggested superior to anthracyclines regimen in LABC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual rate&#xD;
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>correlation of topoisomerase II and pathologic complete response</measure>
    <time_frame>pCR at surgery</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">338</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>100 mg/mÂ² every three weeks (4 cycles) or every two weeks (6 cycles)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically-confirmed breast cancer (operable, locally advanced or inflammatory)&#xD;
&#xD;
          2. Age less than 70 years&#xD;
&#xD;
          3. Female patient&#xD;
&#xD;
          4. Tumor size 2 cm at ultrasound examination.&#xD;
&#xD;
          5. ER-negative tumors defined according to immunohistochemistry (i.e. &lt; 10% of positive&#xD;
             cells after immunostaining).&#xD;
&#xD;
          6. Multifocal and multicentric breast tumors are allowed if all foci are ER-negative.&#xD;
&#xD;
          7. Fixed and frozen samples from the primary tumor, obtained before treatment with&#xD;
             epirubicin, must be available for evaluation of biological markers (topo II alpha gene&#xD;
             and protein, HER-2 gene, p-53 gene, oligonucleotides microarrays).&#xD;
&#xD;
          8. Written informed consent before study registration.&#xD;
&#xD;
          9. Performance status 0 or 1 (ECOG scale)&#xD;
&#xD;
         10. Normal CBC, hepatic and renal functions&#xD;
&#xD;
         11. Normal left ventricular ejection fraction by echocardiography or muga scan&#xD;
&#xD;
         12. Negative pregnancy test for all women of childbearing potential. Patients of&#xD;
             childbearing potential must implement adequate non-hormonal measures to avoid&#xD;
             pregnancy during treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastatic breast cancer&#xD;
&#xD;
          2. Serious medical conditions like:&#xD;
&#xD;
               1. congestive heart failure or unstable angina pectoris, previous history of&#xD;
                  myocardial infarction within 1 year from study entry, uncontrolled arrhythmias.&#xD;
&#xD;
               2. history of significant neurologic or psychiatric disorders&#xD;
&#xD;
               3. active uncontrolled infection&#xD;
&#xD;
               4. active peptic ulcer, unstable diabetes mellitus&#xD;
&#xD;
          3. Concomitant contralateral invasive breast cancer&#xD;
&#xD;
          4. Concurrent treatment with hormonal replacement therapy&#xD;
&#xD;
          5. Concurrent treatment with any other anti-cancer therapy&#xD;
&#xD;
          6. Previous treatment with anthracyclines for breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique D'Hondt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martine Piccart, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Jules Bordet Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>July 16, 2008</last_update_submitted>
  <last_update_submitted_qc>July 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Veronique D'Hondt</name_title>
    <organization>Jules Bordet Institute</organization>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>early breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

